Cynata Therapeutics Limited (ASX:CYP)
Australia
· Delayed Price · Currency is AUD 0.340
-0.015 (-4.23%)
Mar 6, 2026, 4:10 PM AEST
Cynata Therapeutics Revenue
Cynata Therapeutics had revenue of 1.77M AUD in the half year ending December 31, 2025, a decrease of -30.38%. This brings the company's revenue in the last twelve months to 1.69M, down -3.03% year-over-year. In the fiscal year ending June 30, 2025, Cynata Therapeutics had annual revenue of 1.89M, down -18.59%.
Revenue (ttm)
1.69M
Revenue Growth
-3.03%
P/S Ratio
47.85
Revenue / Employee
843.64K
Employees
2
Market Cap
80.73M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 1.89M | -430.50K | -18.59% |
| Jun 30, 2024 | 2.32M | 661.33K | 39.98% |
| Jun 30, 2023 | 1.65M | -6.12M | -78.71% |
| Jun 30, 2022 | 7.77M | 6.22M | 402.60% |
| Jun 30, 2021 | 1.55M | -5.47M | -77.95% |
| Jun 30, 2020 | Pro | Pro | Pro |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| LTR Pharma | 1.13M |
| Alterity Therapeutics | 6.64M |
| Imugene | 3.94M |
| Radiopharm Theranostics | 16.28M |
| Arovella Therapeutics | 3.21M |
| Prescient Therapeutics | 4.27M |
| Paradigm Biopharmaceuticals | 8.45K |
| Neurizon Therapeutics | 5.98M |
Cynata Therapeutics News
- 4 weeks ago - Cynata Therapeutics Limited (CYYNF) Discusses Imminent Clinical Trial Readouts and Key Milestones in Osteoarthritis and Graft-versus-Host Disease Transcript - Seeking Alpha
- 4 months ago - Cynata Therapeutics Limited (CYYNF) Discusses Clinical Trial Progress and Corporate Developments Including GVHD, Osteoarthritis, and Kidney Transplantation Transcript - Seeking Alpha
- 7 months ago - Cynata Therapeutics Limited (CYYNF) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 1 year ago - Cynata Therapeutics Limited (CYYNF) Investor Webinar Transcript - Seeking Alpha
- 5 years ago - Mesoblast Needs A Solution To MSC Scalability Issues - Cynata Therapeutics Has An Answer - Seeking Alpha